Loading
A phase 2 trial of Encorafenib, Cetuximab, Pembrolizumab in colorectal cancer, run by Pfizer, active and no longer recruiting.
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05217446 by Pfizer, with 108 participants enrolled, started 2022-07-11 and due to reach its primary completion in 2026-06-19. Interventions recorded: Encorafenib, Cetuximab, Pembrolizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Cetuximab, Pembrolizumab, Colorectal cancer.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies.
Shares BRAF V600E-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Encorafenib, Cetuximab, Monoclonal antibodies, Small-molecule kinase inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Encorafenib, BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.